Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
New England Journal of Medicine · 12.03.2026 · 394 (11) · 1084-1096
DOI: 10.1056/nejmoa2515458 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 12.03.2026. Verfasst von Othman Al-Sawaf und 53 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Lymphocytic, Chronic, B-Cell, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, AbbVie, Janssen Pharmaceutica.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department I of Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, Cologne, Germany.
- Department of Hematology, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona.
- St. Olavs University Hospital, Department of Hematology, Trondheim, Norway.
- School of Medicine, Università Vita Salute San Raffaele, Milan.
- Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milan.
- Cantonal Hospital of Lucerne, Lucerne, Switzerland.
ORCID-Profile: Othman Al-Sawaf, Matthias Ritgen
Förderung
- Deutsche Forschungsgemeinschaft
- AbbVie
- Janssen Pharmaceutica
- Roche
Zitieren
APA
Al-Sawaf, O., Stumpf, J., Zhang, C., Simon, F., Bosch, F., Feyzi, E., Ghia, P., Gregor, M., Kater, A. P., Lindström, V., Mattsson, M., Niemann, C. U., Staber, P. B., Tadmor, T., Thornton, P., Wendtner, C. M., Janssens, A., Noesslinger, T., Bohn, J. P., …, & CLL17 Trial Investigators (2026). Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 394(11), 1084-1096. https://doi.org/10.1056/nejmoa2515458
Vancouver
Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, et al. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2026;394(11):1084-1096. doi:10.1056/nejmoa2515458
BibTeX
@article{AlSawaf2026,
author = {Al-Sawaf, Othman and Stumpf, Janina and Zhang, Can and Simon, Florian and Bosch, Francesc and Feyzi, Emadoldin and Ghia, Paolo and Gregor, Michael and Kater, Arnon P and Lindström, Vesa and Mattsson, Mattias and Niemann, Carsten U and Staber, Philipp B and Tadmor, Tamar and Thornton, Patrick and Wendtner, Clemens-Martin and Janssens, Ann and Noesslinger, Thomas and Bohn, Jan-Paul and da Cunha-Bang, Caspar and Poulsen, Christian B and Ranti, Juha and Illmer, Thomas and Schoettker, Bjoern and Böttcher, Sebastian and Gaska, Tobias and Vandenberghe, Elisabeth and Clifford, Ruth and Benjamini, Ohad and Frustaci, Anna Maria and Scarfò, Lydia and Sportoletti, Paolo and Schreurs, John and Levin, Mark-David and van der Straaten, Hanneke and van der Klift, Marjolein and Tran, Hoa and de la Serna, Javier and Loscertales, Javier and Lindblad, Oscar and Bergendahl Sandstedt, Anna and Goede, Jeroen and Baumann, Michael and Fink, Anna Maria and Fischer, Kirsten and Ritgen, Matthias and Kreuzer, Karl-Anton and Schneider, Christof and Tausch, Eugen and Stilgenbauer, Stephan and Robrecht, Sandra and Eichhorst, Barbara and Hallek, Michael and CLL17 Trial Investigators, CLL17 Trial Investigators},
title = {Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {11},
pages = {1084--1096},
doi = {10.1056/nejmoa2515458}
}
EUVIMED